

NOVO NORDISK A S  
Form 6-K  
April 28, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

April 28, 2016

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

**Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2016**

**Bagsværd, Denmark, 28 April 2016** – In accordance with Section 10 of the Danish Statutory Order on Issuers’ Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.

Referring to Company Announcement no 29/2016 dated 18 April 2016, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 28 April 2016.

	<b>Number of shares (nominal value DKK 0.20)</b>	<b>Nominal value (DKK)</b>	<b>Number of votes</b>
<b>A shares</b>	<b>537,436,000</b>	<b>107,487,200</b>	<b>107,487,200,000</b>
<b>B shares</b>	<b>2,012,564,000</b>	<b>402,512,800</b>	<b>40,251,280,000</b>

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube

Page 2 of 2

**Further information**

*Media:*

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com

*Investors:*

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com

Kasper Veje +45 3079 8519 kpvj@novonordisk.com

<b>Novo Nordisk A/S</b>	Novo Allé	Telephone:	
Investor Relations	2880 Bagsværd	+45 4444 8888	CVR no:
	Denmark	Internet:	24 25 67 90
		www.novonordisk.com	
		Company announcement No 33 / 2016	

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: April 28, 2016

Lars Rebien Sørensen,

Chief Executive Officer